Medtronic Announces End To Shareholder Infuse Case
Executive Summary
A long-running shareholder case against Medtronic has come to an end after the US Supreme Court refused to hear the plaintiff's appeal.
You may also be interested in...
Medtronic Agrees To Settle Infuse Shareholder Suit
Device manufacturer Medtronic has offered to pay $43m to resolve a lawsuit brought by shareholders. The suit, filed in 2013, claimed that the company defrauded investors via deceptive marketing for its Infuse bone graft product.
Medtronic Expects Settlements Of Infuse Suits
The company said in a US SEC filing that it’s reached agreements to settle almost 6,000 outstanding patient injury suits tied to the spine device. Terms of the settlements weren't disclosed.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.